These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37081695)

  • 41. Safety of stimulant medications for attention deficit hyperactivity disorder in paediatric congenital heart disease.
    Chung LM; Hariharan G; Varma S
    J Paediatr Child Health; 2023 Mar; 59(3):580-588. PubMed ID: 36789801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Attention deficit disorder, stimulant use, and childhood body mass index trajectory.
    Schwartz BS; Bailey-Davis L; Bandeen-Roche K; Pollak J; Hirsch AG; Nau C; Liu AY; Glass TA
    Pediatrics; 2014 Apr; 133(4):668-76. PubMed ID: 24639278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.
    Schneider G; Banaschewski T; Feldman BL; Gustafsson PA; Murphy B; Reynolds M; Coghill DR; Spalding WM
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):285-304. PubMed ID: 30942617
    [No Abstract]   [Full Text] [Related]  

  • 44. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
    Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of stimulants on sleep characteristics in children with attention deficit/hyperactivity disorder.
    O'Brien LM; Ivanenko A; Crabtree VM; Holbrook CR; Bruner JL; Klaus CJ; Gozal D
    Sleep Med; 2003 Jul; 4(4):309-16. PubMed ID: 14592303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Attention-Deficit/Hyperactivity Disorder in 2- to 5-Year-Olds: A Primary Care Network Experience.
    Bannett Y; Feldman HM; Gardner RM; Blaha O; Huffman LC
    Acad Pediatr; 2021 Mar; 21(2):280-287. PubMed ID: 32360494
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study.
    McCabe SE; Dickinson K; West BT; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2016 Jun; 55(6):479-86. PubMed ID: 27238066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Additive effect of congenital heart disease and early developmental disorders on attention-deficit/hyperactivity disorder and autism spectrum disorder: a nationwide population-based longitudinal study.
    Tsao PC; Lee YS; Jeng MJ; Hsu JW; Huang KL; Tsai SJ; Chen MH; Soong WJ; Kou YR
    Eur Child Adolesc Psychiatry; 2017 Nov; 26(11):1351-1359. PubMed ID: 28417257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.
    Sayer GR; McGough JJ; Levitt J; Cowen J; Sturm A; Castelo E; McCracken JT
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):882-888. PubMed ID: 27483130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.
    Santosh PJ; Sattar S; Canagaratnam M
    CNS Drugs; 2011 Sep; 25(9):737-63. PubMed ID: 21870887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of medication by young people with attention-deficit/hyperactivity disorder.
    Sawyer MG; Rey JM; Graetz BW; Clark JJ; Baghurst PA
    Med J Aust; 2002 Jul; 177(1):21-5. PubMed ID: 12088474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Palli SR; Kamble PS; Chen H; Aparasu RR
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):139-48. PubMed ID: 22364400
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder.
    Poulton A
    Expert Rev Neurother; 2006 Apr; 6(4):551-61. PubMed ID: 16623654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.
    Sultan RS; Wang S; Crystal S; Olfson M
    JAMA Netw Open; 2019 Jul; 2(7):e197850. PubMed ID: 31348506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder.
    Guevara J; Lozano P; Wickizer T; Mell L; Gephart H
    Pediatrics; 2002 May; 109(5):733-9. PubMed ID: 11986429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
    Barbaresi WJ; Katusic SK; Colligan RC; Weaver AL; Leibson CL; Jacobsen SJ
    J Dev Behav Pediatr; 2014 Sep; 35(7):448-57. PubMed ID: 25180895
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J; Sikirica V; Mathurin K
    BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of prescription stimulant for Attention Deficit Hyperactivity Disorder in Aboriginal children and adolescents: a linked data cohort study.
    Ghosh M; Holman CD; Preen DB
    BMC Pharmacol Toxicol; 2015 Dec; 16():35. PubMed ID: 26646429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.